Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model

Ianko D. Iankov, Pavlos Msaouel, Cory Allen, Mark J Federspiel, Peggy A. Bulur, Allan B Dietz, Dennis Gastineau, Yasuhiro H Ikeda, James N. Ingle, Stephen J Russell, Evanthia Galanis

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Breast cancer is the second leading cause of malignant effusions in cancer patients. Pleural effusion indicates incurable disease with limited palliative treatment options and poor outcome. Here, we demonstrate the therapeutic efficacy of measles virus (MV) vaccine strain derivative against malignant pleural effusion in an MDA-MB-231 xenograft model of advanced breast cancer. Both systemic intravenous (i.v.) and intrapleural (t.t.) administered virus caused massive infection and syncytia formation in the pleural tumor deposits. Intrapleural administration of 1.5 × 106 plaque-forming units (PFU) total dose of MV significantly improved median survival by approximately 80% compared to the control animal group. Furthermore, we tested human dendritic cells as carriers for delivery of oncolytic MV infection to breast cancer pleural metastases. Carrier-delivered MV infection prevented accumulation of the pleural exudate and also significantly improved the survival of the treated mice. This is the first demonstration of the therapeutic potential of oncolytic virotherapy against malignant pleural effusions in a pre-clinical model of advanced breast cancer.

Original languageEnglish (US)
Pages (from-to)745-754
Number of pages10
JournalBreast Cancer Research and Treatment
Volume122
Issue number3
DOIs
StatePublished - Aug 2010

Fingerprint

Oncolytic Viruses
Malignant Pleural Effusion
Measles virus
Breast Neoplasms
Virus Diseases
Neoplasms
Oncolytic Virotherapy
Measles Vaccine
Survival
Exudates and Transudates
Pleural Effusion
Giant Cells
Palliative Care
Heterografts
Dendritic Cells
Neoplasm Metastasis
Viruses
Control Groups
Therapeutics
Infection

Keywords

  • Breast cancer
  • Measles virus
  • Oncolytic virotherapy
  • Pleural effusion

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Medicine(all)

Cite this

Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model. / Iankov, Ianko D.; Msaouel, Pavlos; Allen, Cory; Federspiel, Mark J; Bulur, Peggy A.; Dietz, Allan B; Gastineau, Dennis; Ikeda, Yasuhiro H; Ingle, James N.; Russell, Stephen J; Galanis, Evanthia.

In: Breast Cancer Research and Treatment, Vol. 122, No. 3, 08.2010, p. 745-754.

Research output: Contribution to journalArticle

Iankov, Ianko D. ; Msaouel, Pavlos ; Allen, Cory ; Federspiel, Mark J ; Bulur, Peggy A. ; Dietz, Allan B ; Gastineau, Dennis ; Ikeda, Yasuhiro H ; Ingle, James N. ; Russell, Stephen J ; Galanis, Evanthia. / Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model. In: Breast Cancer Research and Treatment. 2010 ; Vol. 122, No. 3. pp. 745-754.
@article{14b56430643c44cf967fb66c8018f33f,
title = "Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model",
abstract = "Breast cancer is the second leading cause of malignant effusions in cancer patients. Pleural effusion indicates incurable disease with limited palliative treatment options and poor outcome. Here, we demonstrate the therapeutic efficacy of measles virus (MV) vaccine strain derivative against malignant pleural effusion in an MDA-MB-231 xenograft model of advanced breast cancer. Both systemic intravenous (i.v.) and intrapleural (t.t.) administered virus caused massive infection and syncytia formation in the pleural tumor deposits. Intrapleural administration of 1.5 × 106 plaque-forming units (PFU) total dose of MV significantly improved median survival by approximately 80{\%} compared to the control animal group. Furthermore, we tested human dendritic cells as carriers for delivery of oncolytic MV infection to breast cancer pleural metastases. Carrier-delivered MV infection prevented accumulation of the pleural exudate and also significantly improved the survival of the treated mice. This is the first demonstration of the therapeutic potential of oncolytic virotherapy against malignant pleural effusions in a pre-clinical model of advanced breast cancer.",
keywords = "Breast cancer, Measles virus, Oncolytic virotherapy, Pleural effusion",
author = "Iankov, {Ianko D.} and Pavlos Msaouel and Cory Allen and Federspiel, {Mark J} and Bulur, {Peggy A.} and Dietz, {Allan B} and Dennis Gastineau and Ikeda, {Yasuhiro H} and Ingle, {James N.} and Russell, {Stephen J} and Evanthia Galanis",
year = "2010",
month = "8",
doi = "10.1007/s10549-009-0602-z",
language = "English (US)",
volume = "122",
pages = "745--754",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York",
number = "3",

}

TY - JOUR

T1 - Demonstration of anti-tumor activity of oncolytic measles virus strains in a malignant pleural effusion breast cancer model

AU - Iankov, Ianko D.

AU - Msaouel, Pavlos

AU - Allen, Cory

AU - Federspiel, Mark J

AU - Bulur, Peggy A.

AU - Dietz, Allan B

AU - Gastineau, Dennis

AU - Ikeda, Yasuhiro H

AU - Ingle, James N.

AU - Russell, Stephen J

AU - Galanis, Evanthia

PY - 2010/8

Y1 - 2010/8

N2 - Breast cancer is the second leading cause of malignant effusions in cancer patients. Pleural effusion indicates incurable disease with limited palliative treatment options and poor outcome. Here, we demonstrate the therapeutic efficacy of measles virus (MV) vaccine strain derivative against malignant pleural effusion in an MDA-MB-231 xenograft model of advanced breast cancer. Both systemic intravenous (i.v.) and intrapleural (t.t.) administered virus caused massive infection and syncytia formation in the pleural tumor deposits. Intrapleural administration of 1.5 × 106 plaque-forming units (PFU) total dose of MV significantly improved median survival by approximately 80% compared to the control animal group. Furthermore, we tested human dendritic cells as carriers for delivery of oncolytic MV infection to breast cancer pleural metastases. Carrier-delivered MV infection prevented accumulation of the pleural exudate and also significantly improved the survival of the treated mice. This is the first demonstration of the therapeutic potential of oncolytic virotherapy against malignant pleural effusions in a pre-clinical model of advanced breast cancer.

AB - Breast cancer is the second leading cause of malignant effusions in cancer patients. Pleural effusion indicates incurable disease with limited palliative treatment options and poor outcome. Here, we demonstrate the therapeutic efficacy of measles virus (MV) vaccine strain derivative against malignant pleural effusion in an MDA-MB-231 xenograft model of advanced breast cancer. Both systemic intravenous (i.v.) and intrapleural (t.t.) administered virus caused massive infection and syncytia formation in the pleural tumor deposits. Intrapleural administration of 1.5 × 106 plaque-forming units (PFU) total dose of MV significantly improved median survival by approximately 80% compared to the control animal group. Furthermore, we tested human dendritic cells as carriers for delivery of oncolytic MV infection to breast cancer pleural metastases. Carrier-delivered MV infection prevented accumulation of the pleural exudate and also significantly improved the survival of the treated mice. This is the first demonstration of the therapeutic potential of oncolytic virotherapy against malignant pleural effusions in a pre-clinical model of advanced breast cancer.

KW - Breast cancer

KW - Measles virus

KW - Oncolytic virotherapy

KW - Pleural effusion

UR - http://www.scopus.com/inward/record.url?scp=77955556150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77955556150&partnerID=8YFLogxK

U2 - 10.1007/s10549-009-0602-z

DO - 10.1007/s10549-009-0602-z

M3 - Article

VL - 122

SP - 745

EP - 754

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -